Loading…
Helios Pharma (ჰელიოს ფარმა) — a Tbilisi-based pharmaceutical depot and importer/representative of the Turkish 'Helios Pharmaceuticals' brand (vitamins, escitalopram, anti-parasitics and other therapeutic lines). Very high branded-representation margins (gross ~60–77%), but revenue collapsed after FY2022 (~GEL 8.4m to ~GEL 0.6m by 2024) — winding down. Assets (~GEL 12.8m) far exceed revenue, indicating non-operating assets/investments — treat balance-sheet ratios with care.
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | CAGR |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 3,380 | 4,277 | 4,702 | 4,865 | 8,432 | 3,464 | 645 | -24.1% |
| Total COGS | 1,098 | 1,355 | 2,072 | 1,688 | 2,809 | 1,352 | 149 | -28.3% |
| Gross Profit | 2,281 | 2,923 | 2,630 | 3,177 | 5,623 | 2,112 | 496 | -22.5% |
| Gross Margin | 67.5% | 68.3% | 55.9% | 65.3% | 66.7% | 61.0% | 76.8% | |
| 748 | 842 | 758 | 792 | 870 | 748 | 654 | -2.2% | |
| EBITDA | 1,534 | 2,081 | 1,872 | 2,384 | 4,753 | 1,364 | 158 | nmf |
| EBITDA Margin | 45.4% | 48.6% | 39.8% | 49.0% | 56.4% | 39.4% | 24.5% | |
| Total D&A | 3 | 3 | 3 | 1 | 0 | 1 | 3 | +1.2% |
| EBIT / Operating Income | 1,531 | 2,078 | 1,869 | 2,384 | 4,753 | 1,363 | 161 | nmf |
| Total Interest Income | 0 | 0 | 33 | 193 | 297 | 286 | 411 | +87.4% |
| Total Other Income | 0 | 0 | 343 | 126 | 100 | 90 | 178 | nmf |
| Profit Before Tax | 1,531 | 2,078 | 2,246 | 2,451 | 4,950 | 1,739 | 72 | -40.0% |
| Total Income Tax | 230 | 312 | 336 | 369 | 0 | 113 | 0 | -13.2% |
| Net Profit / (Loss) | 1,301 | 1,766 | 1,910 | 2,082 | 4,950 | 1,626 | 72 | -38.3% |
| Net Margin | 38.5% | 41.3% | 40.6% | 42.8% | 58.7% | 46.9% | 11.1% |
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Ownership & directors from companyinfo.ge (public corporate registry).
Ranked by how close each latest revenue is to this one — not a curated comp set. Open this set in Compare →